# Arimoclomol in Amyotropic Lateral Sclerosis - Open Label Extension Trial

> **NCT03836716** · PHASE3 · TERMINATED · sponsor: **ZevraDenmark** · enrollment: 120 (actual)

## Conditions studied

- Amyotrophic Lateral Sclerosis

## Interventions

- **DRUG:** Arimoclomol

## Key facts

- **NCT ID:** NCT03836716
- **Lead sponsor:** ZevraDenmark
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-09-19
- **Primary completion:** 2021-07-02
- **Final completion:** 2021-07-02
- **Target enrollment:** 120 (ACTUAL)
- **Why stopped:** As a consequence of the results of ORARIALS-01 which did not meet any of its efficacy endpoints. The planned duration was 152 weeks. After termination, the actual mean duration of treatment was approx. 28 weeks (range approx. 2 to 71 weeks).
- **Last updated:** 2023-08-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03836716

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03836716, "Arimoclomol in Amyotropic Lateral Sclerosis - Open Label Extension Trial". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03836716. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*